Scinai Immunotherapeutics (SCNI) Non-Current Debt (2018 - 2026)
Scinai Immunotherapeutics (SCNI) posted Non-Current Debt of $287000.0 for Q1 2026, down 2.38% sequentially from $294000.0 in Q4 2025.
Scinai Immunotherapeutics (SCNI) Non-Current Debt (2018 - 2026) Analysis & Trends
Scinai Immunotherapeutics has reported Non-Current Debt for 9 years, with the latest figure at $287000.0 in Q1 2026.
- Quarterly Non-Current Debt changed N/A year-over-year to $287000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $287000.0 (changed N/A YoY) and the FY2025 annual result came in at $294000.0, up 13.08% from the prior year.
- Non-Current Debt eased to $287000.0 in Q1 2026 per SCNI's latest filing, from $294000.0 in the prior quarter.
- Over five years, Non-Current Debt peaked at $23.3 million in Q2 2023 and troughed at $260000.0 in Q4 2024.
- A 5-year average of $13.0 million and a median of $18.6 million in 2023 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2022 and 2023: Non-Current Debt slumped 99.98% in 2022, then jumped 56.92% in 2023.
- Over 5 years, Non-Current Debt stood at $20.1 million in 2022, then declined by 3.56% to $19.4 million in 2023, then plunged by 98.66% to $260000.0 in 2024, then grew by 13.08% to $294000.0 in 2025, then declined by 2.38% to $287000.0 in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $287000.0, $294000.0, and $293000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.50 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.98 Bn | 53.84 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 8.96 Bn |
| 10 | Scinai Immunotherapeutics | 11.81 Mn | -3.10 Bn | -1.12 Mn | 287,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 287,000.00 |
| Dec 31, 2025 | 294,000.00 |
| Jun 30, 2025 | 293,000.00 |
| Dec 31, 2024 | 260,000.00 |
| Sep 30, 2024 | 280,000.00 |
| Jun 30, 2024 | 19.82 Mn |
| Mar 31, 2024 | 19.51 Mn |
| Dec 31, 2023 | 19.37 Mn |
| Sep 30, 2023 | 18.60 Mn |
| Jun 30, 2023 | 23.29 Mn |
| Mar 31, 2023 | 21.85 Mn |
| Dec 31, 2022 | 20.08 Mn |
| Sep 30, 2022 | 15.63 Mn |
| Jun 30, 2022 | 14.84 Mn |
| Mar 31, 2022 | 20.52 Mn |
| Dec 31, 2021 | 27.16 Mn |
| Sep 30, 2021 | 19.97 Mn |
| Jun 30, 2021 | 64.25 Bn |
| Mar 31, 2021 | 62.35 Bn |
| Dec 31, 2020 | 60.42 Bn |